Invex Therapeutics Ltd
IXC
Company Profile
Business description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Contact
c/- Automic Group
Level 5, 191 St Georges Terrace
PerthWA6000
AUST: +61 1300288664
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.90 | 14.70 | 0.16% |
| CAC 40 | 8,448.27 | 85.13 | 1.02% |
| DAX 40 | 25,224.63 | 213.28 | 0.85% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,717.85 | 131.94 | 1.25% |
| HKSE | 24,892.66 | 239.63 | -0.95% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 66,115.60 | 116.59 | -0.18% |
| NZX 50 Index | 13,763.18 | 107.15 | 0.78% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,823.00 | 16.50 | 0.19% |
| SSE Composite Index | 3,867.03 | 2.67 | 0.07% |